FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2025
0mins
Source: Globenewswire
FDA Fast Track Designation: OKYO Pharma's urcosimod has received Fast Track designation from the FDA for treating neuropathic corneal pain, a condition with no approved therapies, aimed at expediting its development and review process.
Innovative Treatment Approach: Urcosimod is designed to address severe eye pain through a novel mechanism targeting inflammation and nerve damage, with ongoing clinical trials to evaluate its efficacy in patients suffering from this debilitating condition.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
